Physician profile
Frank Ravago
NPI 1447233622
$4,077.02
in general payments reported to CMS, 2019-2025
20 companies · $1,195 in 2025
The $1,195 reported for 2025 was more than what 87% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $230 · 2020: $82.93 · 2021: $286 · 2022: $677 · 2023: $851 · 2024: $754 · 2025: $1,195.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,801.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,800.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,894.65 | 2019-2025 | Breztri, Airsupra, Farxiga |
| Boehringer Ingelheim Pharmaceuticals, INC. | $456.60 | 2020-2025 | Jardiance |
| Abbott Laboratories | $362.14 | 2022-2025 | Freestyle Libre 3 |
| Amgen INC. | $272.32 | 2019-2024 | Repatha, Otezla |
| Glaxosmithkline, LLC. | $252.38 | 2020-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Bayer Healthcare Pharmaceuticals INC. | $174.90 | 2023-2025 | |
| Mylan Specialty L.P. | $103.26 | 2019-2023 | Yupelri |
| Novo Nordisk INC | $94.18 | 2019-2025 | Ozempic, Rybelsus |
| Sunovion Pharmaceuticals INC. | $89.54 | 2019 | |
| Abbvie INC. | $66.77 | 2022-2023 | |
| Rigel Pharmaceuticals, INC. | $53.45 | 2022-2024 | Rezlidhia, Tavalisse |
| Lilly USA, LLC | $52.83 | 2022-2023 | Jardiance |
| Paratek Pharmaceuticals, INC. | $37.81 | 2025 | Nuzyra, Xhance |
| Amarin Pharma, INC. | $37.28 | 2019-2021 | |
| Dexcom, INC. | $27.63 | 2025 | Dexcom G6 Transmitter |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $27.47 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $23.41 | 2025 | Eliquis |
| Avanir Pharmaceuticals, INC. | $20.37 | 2019 | |
| Janssen Pharmaceuticals, INC | $16.30 | 2022 | |
| Pfizer INC. | $13.73 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Frank Ravago listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.